Please upgrade your browser.
Rod Blagojevich, Governor of the State of Illinois, proclaims March as awareness month in support of public information campaign.
The Keystone Program in Personalized Kidney Cancer Therapy to investigate the mechanisms of kidney cancer metastasis and to uncover the molecular signals that anticipate how a kidney tumor will respond to therapies in order to optimize therapy for individual patients.
Late-stage, or Phase III trials of the drug were halted early after interim results showed significantly better survival in patients with advanced kidney cancer who received Everolimus compared to placebos.
Ambit Biosciences today announced the formation of clinical advisory boards that will help the company advance its drug candidates in development for the treatment of blood cancers and solid tumors. The first advisory board will be focused on hematology and oncology, and the second will focus on solid tumors. The boards will guide Ambit on the development and implementation of the company's clinical programs for its kinase inhibitors, including AC220 for acute myeloid leukemia (AML) and AC480 for solid tumors.
U.S. scientists have found a metabolic regulatory molecule known as PGC-1alpha in mice that detects low oxygen and nutrient levels when circulation ceases and activates the formation of blood vessels. This discovery could bring about development of treatments for cancer.
Age, adiposity, and smoking are risk factors for the development of renal cell carcinoma.
A breakthrough therapy shown to extend median overall survival of patients with metastatic (advanced) renal cell carcinoma (RCC), the most common form of kidney cancer,(1,2) has been approved by Health Canada.
New cancer statistics show a rise in cancer deaths in 2005 and an overall drop in the cancer death rate since 1990
American Indians and Alaska Natives have the highest rate of kidney cancer cases and deaths from kidney cancer, the report also shows.
A team of scientists from JILA, a joint institute of the National Institute of Standards and Technology (NIST), and the University of Colorado at Boulder have released a promising study on the correlation between breath and the detection of disease, including kidney cancer.
One London-area man with kidney cancer has access to the treatment he seeks through private insurance, while a second man with the same ailment -- but no private insurance -- is denied the drug he needs.
|Powered by NeonCRM|